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OBJECTIVE — The effects of dietary macronutrient composition on metabolic proﬁles in
patients with type 2 diabetes have been inconsistent. This meta-analysis aimed to elucidate the
effect of replacing dietary fat with carbohydrate on glucose and lipid parameters in patients with
type 2 diabetes.
RESEARCH DESIGN AND METHODS — We searched for randomized trials that
investigated the effects of two kinds of prescribed diets (a low-fat, high-carbohydrate [LFHC]
diet and a high-fat, low-carbohydrate [HFLC] diet); in these studies, energy and protein intake
did not differ signiﬁcantly between the two dietary groups. Nineteen studies that included 306
patientsmetourinclusioncriteria.Mediandietcompositionofcarbohydrate/fatintheLFHCand
HFLC diets was 58%/24% and 40%/40%, respectively.
RESULTS — Changes in values for A1C, fasting plasma glucose (FPG), and total and LDL
cholesteroldidnotdiffersigniﬁcantlybetweentheLFHCandHFLCgroups.However,theLFHC
diet signiﬁcantly increased fasting insulin and triglycerides by 8% (P  0.02) and 13% (P 
0.001),respectively,andloweredHDLcholesterolby6%(P0.001)comparedwiththeHFLC
diet. There were positive associations among the magnitude of changes in FPG, fasting insulin,
andtriglyceridesforthedietsanalyzed.However,stratiﬁedanalysisindicatedthattheincreasein
triglycerides was insigniﬁcant when accompanied by energy intake restriction.
CONCLUSIONS — Our ﬁndings suggested that replacing fat with carbohydrate could de-
teriorate insulin resistance while the adverse effect on triglycerides from the LFHC diet could be
avoidedbyrestrictingenergyintaketoadegreesufﬁcientfortheattainmentofweightreduction.
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M
edical nutrition therapy (MNT) is
the most important aspect of dia-
betes treatment (1). Optimizing
energy intake and macronutrient compo-
sition are especially major topics in MNT.
Whereas it is well-known that caloric
restriction is essential for the achieve-
ment of good glycemic and lipid pro-
ﬁles, mainly through weight loss, the
optimal dietary macronutrient compo-
sition for patients with type 2 diabetes
remains controversial.
Since a high-protein diet is not rec-
ommended for diabetic patients because
of the risk of nephropathy (1), macronu-
trient composition is mainly regulated by
the carbohydrate-to-fat (C/F) ratio. Con-
ventionally,restrictingfatintakehasbeen
promoted to decrease energy intake and
reduce weight (2). However, a low-fat
diet, inevitably accompanied by high car-
bohydrate intake, may increase post-
prandial plasma glucose, insulin, and
triglyceride levels (1). Therefore, the ben-
eﬁtofraisingthedietaryC/Fratioonmet-
abolic control in type 2 diabetes has not
been established. The effects of a low-fat,
high-carbohydrate(LFHC)dietorahigh-
fat, low-carbohydrate (HFLC) diet in
which total energy and protein intake are
consistentinpatientswithtype2diabetes
have often been compared. The aim of
this meta-analysis is to systematically
compare the effects of LFHC and HFLC
diets on glucose and lipid control in pa-
tients with type 2 diabetes.
RESEARCH DESIGN AND
METHODS— We searched MED-
LINE (between 1966 and 2007) and the
Cochrane Library Central Registry of
Controlled Trials (between 1984 and
2007) for relevant publications using the
following medical subject heading terms:
diabetes and (food or diet). We examined
reference lists of those publications to
identifyadditionalstudiessuitableforour
purpose. We restricted the search to ran-
domized controlled trials published in
English. We searched for studies of the
effects of two kinds of prescribed diets
differing according to proportions of car-
bohydrate and fat under conditions that
the prescribed total energy and protein
intakedidnotdiffersigniﬁcantlybetween
groups of patients with type 2 diabetes.
Trials in patients with type 1 diabetes
wereexcluded.Wedesignatedonedietas
the LFHC diet, which was deﬁned as hav-
ing a relatively high C/F ratio, and the
other as the HFLC diet, which had a rel-
ativelylowC/Fratio.Asshownindetailin
Table 1, in examining these studies, we
found that the C/F ratio ranged from 0.60
to 1.56 for the HFLC diets and from 1.67
to 7.30 for the LFHC diets.
Among the studies identiﬁed, we in-
cluded only randomized controlled trials
with measurements of fasting plasma glu-
cose (FPG) and fasting insulin and inter-
vention periods of 1 week. Both
parallel-group and crossover designs
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intervention with a change in the content
or quality of carbohydrate such as an in-
crease in ﬁber and whole grains were ex-
cluded because such diets are high in
ﬁber, which in itself ameliorates glycemia
and lipemia regardless of changes in the
C/F ratio (3,4). Studies of very-low-
calorie or enteral (not oral) diets and
those in which the dosage of hypoglyce-
mic agents was changed during the inter-
vention period were also excluded. One
of three reviewers extracted all studies
that met the eligibility criteria, and a sec-
ond reviewed all extracted data. When
necessary, disagreement was resolved by
discussion with a third author.
Extracted data included features of
thestudydesign(i.e.,crossoverorparallel
designandpresenceofawashoutperiod),
intervention periods, characteristics of
patients (mean age, BMI, percent men,
and percent those using hypoglycemia
agents).Otherextracteddataregardedthe
characteristics of each diet, such as ma-
cronutrient composition; a weight-loss
diet, which was deﬁned as caloric restric-
tion resulting in weight reduction; a
weight-maintenance diet, which was de-
ﬁned by a weight change of 1 kg during
the intervention period, and a monoun-
saturated fat (MUFA) diet within the
HFLC-diet group, which was deﬁned as
the addition of MUFA to the HFLC diet.
We also extracted baseline and ﬁnal
means and statistical dispersions of each
group for the following metabolic pro-
ﬁles: A1C, FPG, fasting insulin, total cho-
lesterol, fasting triglycerides, LDL
cholesterol, HDL cholesterol, and 2-h
postprandiallevelsofglucoseandinsulin.
If VLDL cholesterol but not triglyceride
data were provided, the triglyceride value
was calculated by multiplying VLDL cho-
lesterol  5 according to the Friedewald
formula (5). Also, if HbA1 but not A1C
data were provided, A1C was estimated
by the relation between HbA1 and A1C
concentrations according to the method-
ology of Kilpatrick et al. (6). If necessary,
measures of means and dispersion were
approximated from ﬁgures in the articles
using an image scanner (CanoScan LiDE
500F [resolution 600 dpi]; Canon, To-
kyo, Japan). Study quality was assessed
according to the scale described by Jadad
et al. (7), with each included trial evalu-
ated according to randomization, double
blinding, withdrawals, and dropouts.
The effect on each metabolic proﬁle,
which is expressed as the mean difference
betweenLFHC-andHFLC-dietgroupsin
individual studies, was calculated by sub-
tracting the change from baseline to ﬁnal
values in the HFLC-diet group from that
in the LFHC-diet group. The SE of the
Table 1—Descriptive statistics of studies included in the meta-analysis
Intervention
period
(weeks)
Dropout
(%)
LFHC HFLC
Age
(years)
Men
(%) BMI
Using
antihyperglycemia
agents (%)
Diabetes
duration
(years) n C/F/P (%) n C/F/P (%)
Campbell et al. (1994; ref. 13) 2 N/A 10 55/22/23 10 40/37/23 55 100 26.5 10 5
Chen et al. (1995; ref. 14) 6 N/A 9 55/30/15 9 40/45/15 49 67 27.5 N/A N/A
Coulston et al. (1989; ref. 15) 6 0 8 60/20/20 8 40/40/20 66 63 25.5 75 N/A
Fuh et al. (1990; ref. 16) 2 N/A 11 60/20/20 11 40/40/20 58 100 25.8 100 N/A
Garg et al. (1992; ref. 17) 3 N/A 8 60/25/15 8 35/50/15 63 100 30 0 N/A
Garg et al. (1994; ref. 18) 6 0 42 55/30/15 42 40/45/15 58 79 28.1 100 N/A
Heilbronn et al. (1999a;
ref. 19) 12 17 12 73/10/17 10 50/32/18 58 27 32.9 58 5
Heilbronn et al. (1999b;
ref. 19) 12 15 12 73/10/17 13 50/32/18 58 20 33.1 52 6
Lovejoy et al. (2002a; ref. 20) 4 12 30 58/27/15 30 46/39/15 54 43 33 47 N/A
Lovejoy et al. (2002b; ref. 20) 4 12 30 58/27/15 30 46/39/15 54 43 33 47 N/A
Luscombe et al. (1999;
ref. 21) 4 25 21 53/21/26 21 42/35/23 57 67 30.4 76 6
Miyashita et al. (2004; ref. 22) 4 N/A 11 63/10/27 11 40/35/25 52 73 27 0 N/A
Parillo et al. (1992; ref. 23) 2 0 10 60/20/20 10 40/40/20 53 70 26.7 50 8
Parillo et al. (1996a; ref. 24) 2 0 9 60/20/20 9 40/40/20 48 N/A 24.7 0 6
Parillo et al. (1996b; ref. 24) 2 0 9 60/20/20 9 40/40/20 50 N/A 24.6 100 8
Rodriguez-Villar et al. (2000;
ref. 25) 6 25 12 55/30/15 12 45/40/15 N/A N/A 27.9 N/A 6
Rodriguez-Villar et al. (2004;
ref. 26) 6 15 22 55/30/15 22 45/40/15 61 54 28.3 N/A N/A
Rusmussen et al. (1994; refs.
27, 28) 3 N/A 15 50/30/20 15 30/50/20 57 67 27 47 6
Sestoft et al. (1985; ref. 29) 1.4 N/A 8 50/30/20 8 42/36/22 48 50 22.7 0 5
Simpson et al. (1982; ref. 30) 4 N/A 10 60/22/18 10 35/47/18 58 N/A 26.2 80 6
Storm et al. (1997a; ref. 31) 3 0 15 50/30/20 15 40/45/15 53 53 29.7 73 6
Storm et al. (1997b; ref. 31) 3 0 15 50/30/20 15 40/45/15 53 53 29.7 73 6
Median 4 6 12 58/24/20 12 40/40/20 55 65 27.7 52 6
Minimum 1.4 0 8 8 48 20 22.7 0 5
Maximum 12 25 42 42 66 100 33.1 100 8
C/F/P, proportion of carbohydrate/fat/protein to total energy of the prescribed diet; N/A, not assessed.
Fat and carbohydrate proportions and metabolic proﬁle
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extracted from the reported data or esti-
mated from the SEs of the baseline and
ﬁnal values in the LFHC- and HFLC-diet
groups, assuming a correlation of 0.5 be-
tween the baseline and ﬁnal measures
within each group, according to the for-
mula of Follmann et al. (8), as follows:

SEbaseline
2  SEﬁnal
2  2  0.5
 SEbaseline  SEﬁnal
We chose the percent change from base-
linevaluesbecausethemeanbaselineand
ﬁnal values in patients in each study were
highly skewed. To estimate percent
change, we divided each change from
baseline values and its SE by the baseline
value. When no baseline value was re-
ported, as in some crossover studies, we
summarizedtheinterventioneffectbythe
ratio of the difference in ﬁnal values be-
tween LFHC- and HFLC-diet groups to
the ﬁnal value in the HFLC-diet group
and assumed that the baseline SE was
equal to the ﬁnal SE. This method of esti-
matingpercentchangehaslimitations,es-
pecially in studies without washout
periods. Therefore, we performed a sen-
sitivity analysis to examine the effect of
these studies on the results.
All percent changes were ﬁrstly
pooled with a ﬁxed-effects model (9). For
eachoutcomemeasure,inﬂuenceanalysis
was conducted to detect an outlier (i.e., a
single estimate with an extreme result),
which inﬂuenced overall outcome. Study
heterogeneity was statistically assessed by
Q statistics (9). If heterogeneity was sig-
niﬁcant, the percent changes were sec-
ondarily re-pooled with a random-effects
model (9). Publication bias was assessed
using two formal methods: Begg’s test
(10) and Egger’s test (11). The trim-and-
ﬁll technique (12) was used to investigate
the impact of any suggested bias.
We also calculated the weighted
mean difference (WMD) in individual tri-
alsbymultiplyingeachpercentchangeby
the inverse of its SE squared. We ecolog-
ically examined the mutual association
among each metabolic effect of the LFHC
diet compared with the HFLC diet by
Spearman’s correlation analyses among
WMDs.
Toinvestigatetheeffectofstudychar-
acteristics, stratiﬁed analyses were per-
formed for the following possible
confounders: study design (i.e., whether
each trial used a crossover design and, if
so,whetherthetrialhadawashoutperiod
or data on baseline values), intervention
period (4 vs. 4 weeks), percent the
study of female sex (50 or 50%),
meanage(55vs.55years),BMI(28
vs. 28 kg/m
2), percentage using hypo-
glycemiaagents(zerovs.abovezero),C/F
ratio in the LFHC (3 vs. 3) and HFLC
(1 vs. 1) groups, prescription of the
MUFA diet (yes vs. no), and prescription
of a weight-loss or weight-maintenance
diet. We additionally conducted linear
multivariable regression analyses to de-
termine whether the characteristics of the
patientswereindependentpredictorsthat
inﬂuencedtheeffectoftheLFHCdietver-
sus that of the HFLC diet. In this analysis,
age, BMI, and the carbohydrate propor-
tion in the LFHC and HFLC diets were
enteredascontinuousvariables.APvalue
of 0.05 was considered statistically sig-
niﬁcant. All analyses were performed
with STATA software version 10 (STATA
Corporation, College Station, TX).
RESULTS
Descriptive statistics on studies
included in the meta-analysis
(Table 1)
Of 2,203 potentially relevant publica-
tions based on search terms and 22 ref-
erencesobtainedfrommanualsearches,
19 (13–31) met the inclusion criteria.
Four articles (19,20,24,31) included
two trials in one study, and two articles
(27,28) used the same cohort. Finally,
22trials(306patients)wereincludedin
our analyses. Studies included in the
current analysis had intervention peri-
ods ranging from 10 days to 6 weeks
and patient numbers ranging from 8 to
42. Means  between-study SDs for the
mean study characteristics from 22 tri-
als were as follows: age 55  5 years,
percent men 63  23, BMI 28  3 kg/
m
2, percent using hypoglycemia agents
52  31, and diabetes duration 6  1
years.
Ten studies (15,18–21,23–26,31)
described the number of dropouts, and
nine (13,14,16,17,22,27–30) did not.
The dropout rate ranged from 0 to 25%.
Noneofthe19articlesdescribedmethods
of randomization, which led to a low
quality score for the trial. A crossover de-
sign was used in 17 studies (13–
18,20,21,23–31) (with 19 trials),
whereas a parallel design was used in two
studies (19,22) with three trials. Median
carbohydrate/fat proportion of total en-
ergy (C/F ratio) in the LFHC and HFLC
diets was 58%/24% (2.4) and 40%/40%
(1.0), respectively. Three studies
(19,22,26) with 4 trials prescribed a
weight-loss diet, and 11 studies
(13,14,17–19,21,23–25,27,28) with 11
trials provided a MUFA diet to the HFLC-
diet group.
Overall effects of the LFHC diet
compared with those of the HFLC
diet on metabolic outcomes and
study heterogeneity
Table 2 provides a summary of pooled
estimates of various outcome measures.
There were no signiﬁcant differences in
the reduction in A1C, total cholesterol,
and LDL cholesterol between the LFHC
and HFLC diets. However, the LFHC diet
produced signiﬁcant increases in fasting
insulin and triglycerides levels of 8.4%
(P  0.02) and 13.4% (P  0.001), re-
spectively, and a signiﬁcant reduction in
HDL cholesterol compared with that as-
sociated with the HFLC diet. Two-h glu-
cose and insulin values were higher in the
LFHC-diet group than in the HFLC-diet
group by 10.3% (P  0.001) and 12.8%
(P  0.001), respectively.
Inﬂuence analyses indicated that
there were a few outliers for percent
change in total (22), HDL (22), and LDL
(29) cholesterol (see online appendix Ta-
bles A1 and A2, available at http://care.
diabetesjournals.org/cgi/content/full/
dc08-1716/DC1). When these trials were
omitted from the analyses, percent
change in total cholesterol, HDL choles-
terol, and LDL cholesterol signiﬁcantly
changed from 0.0% (95% CI 2.1 to
2.0) to 1.6% (4.5 to 1.3; P  0.03),
from10.4%(12.2to8.6)to5.6%
(2.9 to 8.4; P  0.001), and from
3.0% (6.3 to 0.4) to 0.1% (4.1 to
3.8; P  0.001), respectively. These out-
lyingtrialscomprisedalargepartofstudy
heterogeneity in percent change in total,
HDL, and LDL cholesterol (22.2, 59.1,
and 53.0%, respectively.) Therefore, they
were excluded from the following analy-
ses for the outcome that they affected. Af-
ter omission of these outliers, there was
no evidence of signiﬁcant study heteroge-
neity (P  0.4 for all outcomes).
Relationships among the magnitude
of effects on metabolic proﬁles
Ecological analyses showed trends indi-
cating that the WMD in FPG was posi-
tively associated with that in fasting
insulin (r  0.45; P  0.04) and triglyc-
erides (r  0.59; P  0.004) and that the
WMD in fasting insulin and triglycerides
was mutually associated (r  0.43; P 
0.04).Theseassociationsremainedsignif-
Kodama and Associates
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weight-loss diet was prescribed (FPG vs.
fasting insulin, r  0.58 and P  0.004;
FPG vs. triglycerides, r  0.44 and P 
0.04; and fasting insulin vs. triglycerides,
r  0.44 and P  0.04).
Test of publication bias
Table 2 also shows data on publication
bias and its likely effect on estimates of
outcome according to the trim-and-ﬁll
method (12). There was a relatively
strong suspicion of publication bias for
HDL cholesterol (Egger’s test, P  0.08
for HDL cholesterol; recommended level
ofsigniﬁcance,P0.10[32]).According
to results of the compensatory trim-and-
ﬁll method, the effect of publication bias
would slightly underestimate the adverse
effect of the LFHC diet.
Sensitivity analysis
Results of our stratiﬁed analysis to detect
characteristics of studies and patients in-
cluded in our analyses that might have
modulated study outcomes are shown in
Table3.Ofthe17studieswithacrossover
design, 9 with 10 trials (14–16,21,23–
26,29) did not include a washout period,
which could lead to an underestimation
due to a carryover effect (33). Moreover,
none of these studies had baseline data.
However, the effect of these nine studies
on results was not signiﬁcant for any of
the measures.
The elevation in fasting insulin was
remarkable (17.1%; P  0.001) in LFHC
diets with a C/F ratio 3 (in this case, an
LFHC diet with 60% carbohydrate and
20% fat of total energy) while the C/F
ratio in the LFHC diet did not inﬂuence
triglycerides. There was a greater eleva-
tion in triglycerides (21.0%; P0.001)
with the LFHC diet when the LFHC diet
and MUFA diet were compared; i.e.,
MUFA was replaced with carbohydrate.
However, the magnitude of the elevation
in fasting insulin did not differ between
the MUFA diet and non-MUFA diet (i.e.,
regardless of dietary fat quality). Whereas
a larger elevation in triglycerides was ob-
served in trials limited to weight-
maintenance diets, the LFHC diet did not
signiﬁcantly elevate triglycerides com-
paredwiththeHFLCdietwhenonlytrials
with weight-loss diets were examined
(i.e., diets for weight loss) (P  0.48).
The elevation in fasting insulin was
greater in younger and leaner patients in
responsetotheLFHCdietcomparedwith
that in response to the HFLC diet. More-
over, mean age and BMI were indepen-
dent predictors of percent change in
fasting insulin. Multiple regression analy-
sis indicated that every 1 kg/m
2 of BMI
and 1 year of age were independently
associated with a greater elevation in fast-
inginsulinby2.6%(P0.002)and1.7%
(P  0.005), respectively. For patients
not taking antihyperglycemic drugs, the
LFHCdietcouldbemoreharmfulforfast-
ing insulin than the HFLC diet. However,
because only a few studies included pa-
tients not receiving antihyperglycemic
drugs, the results should perhaps be in-
terpreted with caution.
CONCLUSIONS— Although central
to MNT, the inﬂuences of various dietary
C/F ratios on glycemic control and lipid
proﬁles in patients with type 2 diabetes
have not been systematically reviewed.
Our meta-analysis is the ﬁrst to quantify
theeffectoftheLFHCdietcomparedwith
that of the HFLC diet on each metabolic
outcome.
Our results fundamentally support
current dietary guidelines (1) stating that
replacing fat with carbohydrate signiﬁ-
cantly elevates postprandial glucose and
insulin levels when total energy intake is
consistent. We additionally found that
the LFHC diet signiﬁcantly elevated fast-
inginsulincomparedwiththeHFLCdiet,
with marked elevations noted when the
C/F ratio was 3. Moreover, there were
signiﬁcantly positive relationships among
the change in FPG and the magnitude of
theelevationinfastinginsulinandtriglyc-
erides, independent of energy restriction
for weight control.
Postprandial hyperglycemia with
postprandial hyperinsulinemia and fail-
ure to maintain glucose homeostasis are
often clustered in insulin-resistant indi-
viduals, who are representative of those
with type 2 diabetes (34). This suggests
that an LFHC diet is unfavorable com-
pared with an HFLC diet for insulin-
resistant patients, at least when energy
intake is consistent. However, our ﬁnd-
ings do not support the beneﬁt of an ex-
tremely high-fat diet because the
carbohydrate proportion in the HFLC di-
ets included in our analyses was 50%.
Moreover, we cannot comment on the
possible beneﬁt of a high-carbohydrate
diet with a high-ﬁber component because
we excluded studies investigating the ef-
fectofsuchadiet.Moreover,thereiscon-
cern that increased fat intake ad libitum
maypromoteweightgain(35).Itisworth
repeating that total caloric intake and nu-
Table 2—Overall percent changes resulting from LFHC versus HFLC diet on metabolic proﬁles and data on publication bias and their likely
effect on the estimates
A1C FPG
2-h
glucose
Fasting
insulin
2-h fasting
insulin
Total
cholesterol Triglycerides
HDL
cholesterol
LDL
cholesterol
Trials (n) 10 22 10 22 9 20 22 20 16
Overall percent change 1.5 0.3 10.3 8.4 12.8 1.6 13.4 5.6 0.1
95% CI 5.3 to 2.3 2.8 to 3.4 6.7–13.9 1.3–15.6 5.2–20.4 1.3 to 4.5 7.1–19.8 8.4 to 2.9 3.8 to 4.1
P 0.70 0.87 0.001 0.02 0.001 0.27 0.001 0.001 0.94
Publication bias
Begg’s 0.80 0.82 0.25 0.30 0.40 0.85 0.48 0.75 0.86
Egger’s 0.47 0.30 0.12 0.13 0.16 0.26 0.75 0.08 0.92
Trim and ﬁll
Fill* 7
Adjusted† 7.6
95% CI 10.2 to 5.0
*Studies (n) added by the trim-and-ﬁll method. †Percent change after adjustment for publication bias by the trim-and-ﬁll method. Begg’s, Begg’s adjusted rank
correlation test; Egger’s, Egger’s regression asymmetry test.
Fat and carbohydrate proportions and metabolic proﬁle
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metabolic control regardless of macronu-
trient proportions (1).
Changes in FPG and A1C did not dif-
fer between the two diets despite signiﬁ-
cant elevations in 2-h and fasting insulin
with the LFHC diet. One possible expla-
nationisthattheelevationinpostprandial
glucoselevelwasovercompensatedforby
increased insulin secretion. However,
only three studies concurrently assessed
A1C, fasting insulin, and FPG values,
with an intervention period of, at most, 6
weeks. Therefore, we could not conclude
whethertheelevationinpostprandialglu-
cose and insulin level achieved by raising
the dietary C/F ratio leads to the deterio-
ration of glycemic control represented by
elevations in FPG and A1C.
A previous meta-analysis suggested
that replacing carbohydrate with MUFA
reduced fasting triglycerides in patients
with type 2 diabetes on weight-
maintenance diets (36); this was sup-
ported by our results. However, it is
uncertain whether the effect on triglycer-
ides was caused by the C/F ratio or the
ratio of energy from MUFA to total en-
ergy. Moreover, whether the effect of this
replacement was independent of that of a
weight-loss diet has not been investi-
gated. According to our stratiﬁed analy-
ses, no dose-response relationship
between the C/F ratio in the LFHC diet
and the elevation in triglycerides was in-
dicated, although replacement of the
MUFA diet with the LFHC diet induced a
greater elevation in triglycerides. More-
over, the LFHC diet did not signiﬁcantly
elevate triglycerides compared with the
HFLC diet when a weight-loss diet was
prescribed. Therefore, controlling total
caloricintakeandthequalityofdietaryfat
appear to be more important than carbo-
hydrateandfatcompositioninimproving
triglycerides levels. In other words, these
ﬁndings suggest that a high-carbohydrate
diet has little harmful effect on triglycer-
ideslevelsifsuchadietprovidessufﬁcient
energy restriction for weight control.
Ourstudyhassomelimitations.First,
althoughweomittedstudiesinvestigating
the effect of high-carbohydrate diets that
were also high in dietary ﬁber, it is possi-
ble that the additional phytochemicals
(including ﬁber itself), which are inevita-
bly accompanied by a substantial amount
of carbohydrate, inﬂuence the metabolic
effects regardless of the change in C/F ra-
tio. Second, we assumed that energy in-
take from the two diet groups would be
similar if a weight-maintenance diet was
equal to an isocaloric diet based on evi-
dence of the meta-analysis by Bravata et
al. (37) that indicated that weight change
was associated with restriction of caloric
intakebutnotreducedcarbohydratecon-
tent. However, some recent studies
showed that low-carbohydrate diets re-
sulted in greater weight loss than low-fat
diets despite their similar energy content
(38), as is often the case with high-ﬁber
diets (e.g., whole grains) (39). More in-
vestigation is needed to determine
whether the relationship between change
in energy intake and body weight is inde-
pendent of the proportions of dietary car-
bohydrate and fat. Third, few studies
investigated long-term effects (e.g., 2
months) of changing the proportions of
carbohydrate and fat on metabolic pro-
ﬁles in patients with type 2 diabetes. Ac-
tually, a larger elevation in fasting insulin
inassociationwiththeLFHCdietwasob-
served for an intervention period of 4
weeks compared with 4 weeks but
withoutstatisticalsigniﬁcance(P0.10).
Possibly, a prolonged intervention in-
volving changes in macronutrient com-
position causes some adaptation of
insulin metabolism. Fourth, most studies
provided insufﬁcient data about baseline
glucose and lipid levels, and few focused
on black or Asian patients. Therefore, the
current meta-analysis provides limited
suggestions on identifying patients for
whom a low-fat or low-carbohydrate diet
is especially effective in terms of their cir-
cumstances or metabolic proﬁles (1).
Future studies focused on the follow-
ing are suggested: 1) providing a possible
explanation for the greater adverse effect
on the fasting insulin by the LFHC diet
than by the HFLC diet, especially in
younger and leaner individuals; 2) identi-
fying the long-term effect of a low-
carbohydrate diet on factors other than
metabolic effects (e.g., adaptation in glu-
cose and lipid metabolism, ad libitum en-
ergy intake in patients with type 2
diabetes or obesity [40]) and the safety of
such a diet (e.g., with regard to the diges-
tive system); and 3) addressing whether a
subject’s medication status and the char-
acteristics of diabetes drugs could inﬂu-
encetheeffectofchangingthedietaryC/F
ratio in patients with type 2 diabetes.
In conclusion, replacement of dietary
fat with carbohydrate is not recom-
mendedforimprovementofinsulinresis-
tance in patients with type 2 diabetes
under conditions whereby total energy
and protein intake and the content of car-
bohydrate are similar and the proportion
of carbohydrate to total energy is 30%.
We found that younger and leaner pa-
tientshadhigherfastinginsulinresponses
with the LFHC diet, although the biolog-
icalmechanismwasnotfullyinvestigated.
The LFHC diet also adversely affects trig-
lycerides and HDL cholesterol compared
with the HFLC diet. However, energy re-
striction and dietary fat quality seemed
more important for lowering the triglyc-
eride concentration than the proportion
of carbohydrate and fat.
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